Acumen Pharmaceuticals(ABOS)
搜索文档
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
Newsfilter· 2024-05-09 05:47
CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024, at 8:55 a.m. PT (11:55 a.m. ET). The live webcast may be accessed under the Investors tab on www.acum ...
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
Newsfilter· 2024-04-16 20:00
Sabirnetug在早期阿尔茨海默病患者中的临床和生物标志物结果 - Acumen Pharmaceuticals, Inc.将在2024年AAN年会上展示关于sabirnetug在早期阿尔茨海默病患者中的全面临床和生物标志物结果[1] - Sabirnetug是第一个临床上证明选择性靶向AβOs的人源化单克隆抗体,旨在作为早期阿尔茨海默病的潜在最佳抗体治疗[3] - INTERCEPT-AD的结果显示,sabirnetug在早期阿尔茨海默病患者中表现出良好的安全性和耐受性,且对靶标的作用明显[4]
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease
Newsfilter· 2024-04-04 20:00
Lonza to manufacture Acumen's monoclonal antibody, sabirnetug (ACU193), for clinical development and commercialization, if approvedSabirnetug is the first monoclonal antibody candidate to enter the clinic developed to selectively target toxic soluble amyloid beta oligomers, which evidence indicates are a primary underlying cause of Alzheimer's disease (AD)Acumen is on track to initiate a Phase 2 clinical trial evaluating sabirnetug in the first half of 2024 CHARLOTTESVILLE, Va. and BASEL, Switzerland, April ...
Why Acumen Pharmaceuticals (ABOS) Stock Might be a Great Pick
Zacks Investment Research· 2024-04-03 21:41
ABOS公司盈利预期 - ABOS公司在医疗 - 生物医学和遗传学领域的盈利预期正在稳步上升[1] - 过去两个月,ABOS当前季度盈利预期从每股亏损26美分缩小至每股亏损24美分,全年盈利预期也有所改善[4] - ABOS目前持有Zacks Rank 3 (Hold),显示公司前景积极[4] ABOS公司行业地位 - ABOS所在的医疗 - 生物医学和遗传学行业目前排名第74,显示其在行业中处于有利位置[2] - ABOS所在行业处于前三分之一的位置,近期盈利预期稳步提升,对于寻找优质投资标的的投资者来说,ABOS是一个非常有吸引力的选择[5]
Acumen Pharmaceuticals(ABOS) - 2023 Q4 - Earnings Call Presentation
2024-03-26 21:21
Corporate Presentation March 2024 1 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen's goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as "believes," "expects," "anticipates," "could," "would," "seeks," "aims," "plans," "potential," "will" and similar expr ...
Acumen Pharmaceuticals(ABOS) - 2023 Q4 - Annual Report
2024-03-26 21:16
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________ FORM 10-K __________________________ x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2023 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-40551 __________________________ Acumen Pharmaceuticals, Inc. (Exact name of registrant ...
Acumen Pharmaceuticals(ABOS) - 2023 Q4 - Annual Results
2024-03-26 19:42
Sabirnetug单克隆抗体 - Sabirnetug (ACU193)是一种单克隆抗体,高度选择性地针对有毒的AβOs,具有潜在的认知疗效和改善安全性[3] - Sabirnetug是第一个证明具有选择性靶向AβOs的mAb[27] - Sabirnetug对AD患者的毒性AβOs具有高选择性[39] Sabirnetug的药效和药代动力学特性 - Sabirnetug在早期阿尔茨海默病患者中显示出对淀粉样斑块的减少效果,且剂量接近最大目标效应,为下一阶段的研究提供了指导[4] - Sabirnetug与AβOs的靶向结合呈剂量比例关系,支持其作用机制,并有助于下一阶段的剂量选择[5] - Sabirnetug在CSF中的暴露量与剂量和剂量方案成比例,表明其药代动力学特性[6],[7],[8],[9],[10],[11],[12] Sabirnetug的安全性 - Sabirnetug具有低发生ARIA-E的引人注目的安全性[24] Sabirnetug的其他特性 - Sabirnetug在人类AD大脑切片中与非Thioflavin S阳性的Aβ结合很少或没有[29] - Sabirnetug能够阻止AβOs对神经元的毒性[30] - Sabirnetug在转基因小鼠脑中以剂量依赖的方式结合靶AβOs[32] Sabirnetug的未来展望 - 预计在2024年上半年启动ALTITUDE-AD临床研究[34] Sabirnetug的知识产权 - Sabirnetug的全球知识产权包括19个国家的已颁发专利[38] CSF生物标志物相关性 - CSF神经粒蛋白和pTau181的变化之间存在显著相关性[42] 其他相关药物信息 - 2022年9月28日,Eisai / Biogen发布了关于leqembiTM的消息[47] - 2023年5月3日,Eli Lilly发布了关于donanemab的消息[47] - 2019年12月5日,Biogen详细介绍了关于AduhelmTM的案例[47] 不同药物的ARIA-E发生率比较 - solanezumab在EXPEDITION 3(第3阶段)中的PC治疗组的ARIA-E为0.2%[48] - aducanumab在EMERGE(第3阶段)中的PC治疗组的ARIA-E为0.1%[48] - aducanumab在ENGAGE(第3阶段)中的PC治疗组的ARIA-E为2.2%[48] - donanemab在TRAILBLAZER-2(第3阶段)中的PC治疗组的ARIA-E为26.1%和34.4%[48] - lecanemab在Clarity-AD(第3阶段)中的PC治疗组的ARIA-E为3.0%和25.6%[48]
Is Acumen Pharmaceuticals (ABOS) Outperforming Other Medical Stocks This Year?
Zacks Investment Research· 2024-03-21 23:46
Acumen Pharmaceuticals, Inc. - Acumen Pharmaceuticals, Inc. 是医疗组中排名第四的公司[2] - Acumen Pharmaceuticals, Inc. 目前的Zacks排名为2(买入)[3] - Acumen Pharmaceuticals, Inc. 今年迄今为止的回报率为8.1%,高于医疗行业的平均回报率6.8%[4] - Acumen Pharmaceuticals, Inc. 属于医疗-生物医学和遗传学行业,排名第80[7] Ayr Wellness Inc. - Ayr Wellness Inc. 今年迄今为止的回报率为12%,表现优于医疗行业[5] - Ayr Wellness Inc. 目前的Zacks排名为2(买入)[6] - Ayr Wellness Inc. 属于医疗-产品行业,排名第89[8] - 投资者应继续关注Acumen Pharmaceuticals, Inc. 和Ayr Wellness Inc.,因为它们可能会保持良好的表现[9]
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
Newsfilter· 2024-03-21 20:00
- Company on track to initiate Phase 2 trial evaluating sabirnetug in first half of 2024 CHARLOTTESVILLE, Va., March 21, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that the Company will present data from its Phase 1 INTERCEPT-AD study evaluating sabirnetug (ACU193) in early AD during an Emerging S ...
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
Newsfilter· 2024-03-20 04:00
公司财务公告 - Acumen Pharmaceuticals, Inc.宣布将于2024年3月26日公布2023年第四季度和年度财务结果[1] - 公司将在东部时间上午8:00举行电话会议和现场音频网络研讨会,提供业务和财务更新[1] 参与方式 - 参与现场电话会议,请使用提供的链接进行注册,并至少提前一天注册[2] 网络研讨会信息 - 网络研讨会音频将在公司网站的投资者部分提供至少30天的存档版本[3] 公司信息 - Acumen Pharmaceuticals, Inc.总部位于弗吉尼亚州夏洛茨维尔,还在印第安纳州印第安纳波利斯和马萨诸塞州牛顿设有额外办公室[4]